European Commission Approves MSD’s ENFLONSIA™ for Prevention of RSV Lower Respiratory Tract Disease in Infants

MSD has announced that the European Commission has approved ENFLONSIA™ (clesrovimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.

Clesrovimab is a preventive, long-acting monoclonal antibody designed to provide direct, rapid and durable protection for five months, which typically covers one RSV season. It is administered using non-weight-based dosing.